CANCER IMMUNOTHERAPY • HUMAN PHASE 3 EVIDENCE • OCTOBER 2026

Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence in Major Trial

Evidence status: Positive interim phase 3 results reported by the trial sponsors and presented at ESMO 2026 in a specific cancer population. Investigational treatment; not evidence of general aging reversal or longer lifespan.

What happened?

The global, randomized, double-blind INTerpath-001 trial enrolled 1,137 adults with high-risk stage IIB–IV cutaneous melanoma completely removed by surgery. Participants received pembrolizumab (an immune-checkpoint inhibitor) plus either personalized mRNA therapy intismeran autogene or placebo.

Results in context

At a median follow-up of 24.6 months, two-year recurrence-free survival was 82.2% with the combination versus 70.0% with pembrolizumab alone—an absolute difference of 12.2 percentage points. The hazard ratio for recurrence or death was 0.58, corresponding to a 42% relative reduction in the measured hazard, not a 42-percentage-point absolute reduction. Two-year distant-metastasis-free survival was 88.5% versus 80.2% (hazard ratio 0.62).

How it works

Researchers sequence a patient's tumor to identify mutations that may produce distinctive proteins called neoantigens. The individualized mRNA therapy can encode up to 34 selected neoantigens, seeking to train immune cells to recognize remaining cancer cells. Pembrolizumab blocks PD-1 signaling, helping T cells sustain their anti-tumor response.

Updated interpretation — October 28, 2026

The sponsor-reported interim Phase 3 results presented at the 2026 ESMO Congress support a clinically meaningful reduction in melanoma recurrence and distant metastasis after surgery. At two years, recurrence-free survival was 82.2% versus 70.0%, an absolute improvement of 12.2 percentage points. The hazard ratio of 0.58 describes a 42% relative reduction in the hazard of recurrence or death during follow-up; it is not a 42% increase in overall survival. Overall-survival data remain immature, with no statistically significant overall-survival difference at this interim analysis (HR 0.77; 95% CI 0.45–1.31; P = .33). The vaccine remains investigational and is not FDA-approved.

Risks and unanswered questions

The treatment remains investigational, and overall-survival results are not yet mature. The study cannot yet show that patients live longer. Sponsor-reported treatment-related grade 3–5 adverse events occurred in 14.2% receiving the combination and 13.4% receiving pembrolizumab alone; these are distinct from all-cause grade 3 or higher adverse events (23.6% versus 20.3% in conference reporting). Fever, injection-site pain and fatigue were common. Longer follow-up, regulatory review and real-world effectiveness assessments are still needed.

Why MKP is following it

This is a clinically meaningful advance in disease-specific cancer prevention after surgery and an important demonstration of personalized mRNA immunotherapy in a large human trial. Preventing cancer recurrence may preserve years of healthy life, but it should not be confused with reversing biological aging, rejuvenating the immune system generally, or proving extension of human lifespan.

Sources and further reading

Merck/Moderna initial Phase 3 announcement (August 19, 2026); AJMC detailed trial-results reporting (October 22, 2026); ClinicalTrials.gov: NCT05933577; Merck/Moderna October 22, 2026 trial-results release (sponsor statement); The ASCO Post independent clinical reporting.

Educational research summary; not medical advice. Updated October 28, 2026.

← Back to MKP home